# gccF Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *gccF* gene encodes a membrane-anchored metallo-β-lactamase (MBL) and peptidoglycan-binding protein, conferring resistance to β-lactam antibiotics and contributing to biofilm formation.
- *gccF* expression is tightly regulated by the CroRS two-component system, which senses cell wall stress induced by β-lactams, and is further modulated by translational frameshifting and alternative start codon usage, generating functional isoforms.
- Clinically significant missense mutations in the MBL domain (e.g., Ser208Phe, Trp230Cys) are associated with resistance to specific cephalosporins and carbapenems, while truncating mutations in the PG domain can lead to hypervirulence or altered biofilm phenotypes.
- *gccF* contributes to immune evasion by sequestering immunostimulatory peptidoglycan fragments and by interfering with host autophagy, facilitating intracellular bacterial survival.
- Therapeutic strategies targeting *gccF* include zinc-chelating agents (e.g., EDTA) combined with β-lactams to restore antibiotic susceptibility and monoclonal antibodies targeting the peptidoglycan-binding domain to enhance bacterial clearance.

---

## Executive Summary & Key Metadata

The **gccF** gene encodes a multifunctional protein that operates at the intersection of bacterial cell wall remodeling, antimicrobial resistance (AMR) dissemination, and host innate immune modulation. Originally identified in Gram-positive pathogens, the gccF gene product (UniProt E9K9Z1) is a membrane-anchored enzyme with a C-terminal peptidoglycan-binding domain and an N-terminal metallo-β-lactamase (MBL) fold. This structural duality positions gccF as a critical determinant of β-lactam antibiotic resistance and a modulator of host-pathogen interactions.

The protein's clinical relevance has expanded beyond its canonical role in antibiotic hydrolysis. Recent functional genomics screens have implicated gccF in the regulation of bacterial biofilm formation, horizontal gene transfer (HGT) via conjugation, and the subversion of host autophagic clearance. In clinical isolates, specific missense mutations within the MBL domain correlate with extended-spectrum cephalosporin resistance, while truncating mutations in the C-terminal domain are associated with hypervirulent phenotypes in *Enterococcus faecium* and *Staphylococcus aureus* lineages.

The table below summarizes the essential genomic and proteomic identifiers for gccF.

| **Attribute** | **Value** |
|---------------|-----------|
| HGNC Symbol | gccF |
| UniProt Accession | E9K9Z1 |
| Representative PDB ID | true (structural homologs available; see Section 2) |
| Chromosomal Locus | Variable; typically plasmid-borne or chromosomal integrative conjugative element (ICE) in Firmicutes |
| Primary Molecular Function | Metallo-β-lactamase (MBL) fold hydrolase; peptidoglycan glycosyltransferase/endopeptidase activity |
| Disease & Pathology Associations | β-lactam resistance, biofilm-associated chronic infections, bacteremia, endocarditis |
| Subcellular Localization | Gram-positive cell membrane (single-pass transmembrane) |
| Expression Pattern | Constitutive; upregulated under β-lactam stress and during biofilm maturation |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Mobilization

The gccF locus is not fixed to a single chromosomal coordinate across bacterial species. In *Enterococcus faecium* strain Aus0004, gccF resides within a 48.7 kb integrative conjugative element (ICE) designated ICE*Efm*1, inserted at the 3' end of the *rpsI* gene (encoding ribosomal protein S9). In *Staphylococcus aureus* MRSA252, a homologous sequence is found on the plasmid pMRSA252 (accession BX571857), flanked by IS256 insertion sequences. This genomic plasticity is a hallmark of AMR genes, facilitating rapid dissemination via conjugation and transposition.

The core promoter region of gccF contains a canonical −10 box (TATAAT) and a −35 box (TTGACA) recognized by the housekeeping sigma factor σ^A. However, transcriptional start site (TSS) mapping via 5' RACE has identified a secondary promoter located 120 bp upstream of the primary TSS, which is induced by sub-inhibitory concentrations of cefotaxime. This stress-responsive promoter is regulated by the two-component system CroRS, which senses cell wall damage and upregulates gccF transcription by 8- to 12-fold within 15 minutes of antibiotic exposure [<a href="#ref-1">1</a>].

### 1.2 Promoter Architecture and Regulatory Elements

The gccF promoter region (positions −200 to +50 relative to the primary TSS) contains several cis-acting elements:

- **CroR binding box**: A direct repeat of 9 bp (5'-TTGTTATCA-3') located at positions −70 to −52. CroR, the response regulator of the CroRS system, binds this sequence as a dimer, recruiting RNA polymerase and displacing the nucleoid-associated protein H-NS (in Gram-negatives) or Lsr2 (in actinobacteria) [<a href="#ref-1">1</a>].
- **Bent DNA motif**: A poly(A) tract (A_6) at positions −40 to −35 induces intrinsic DNA curvature, facilitating promoter escape.
- **Riboswitch-like element**: The 5' untranslated region (UTR) of gccF mRNA (nucleotides +1 to +180) folds into a stem-loop structure that sequesters the Shine-Dalgarno sequence. In the presence of free D-alanyl-D-alanine dipeptides (cell wall precursors), the riboswitch undergoes a conformational shift, exposing the ribosome binding site and enhancing translation initiation by 3-fold [<a href="#ref-2">2</a>].

### 1.3 Alternative Splicing and Isoform Diversity

Although bacteria lack canonical spliceosomes, gccF exhibits transcriptional heterogeneity through two mechanisms:

1. **Programmed translational frameshifting**: A slippery sequence (5'-AAAAAAG-3') at codon 214 causes a −1 frameshift in approximately 15% of translation events, producing a C-terminally extended isoform (gccF-L) with an additional 37 amino acids. This extension contains a second transmembrane helix, anchoring the protein in an inverted orientation on the membrane.
2. **Alternative start codon usage**: A downstream in-frame start codon (GTG at codon 45) produces a truncated isoform (gccF-S) lacking the N-terminal cytoplasmic signaling domain. gccF-S is predominantly expressed during stationary phase and functions as a dominant-negative regulator of the full-length protein by sequestering peptidoglycan fragments [<a href="#ref-3">3</a>].

The ratio of gccF-FL (full-length) to gccF-S is dynamically regulated by the stress-responsive protease ClpP, which cleaves gccF-FL at a conserved Ala-Ser bond (residues 42–43) under oxidative stress conditions [<a href="#ref-3">3</a>].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The gccF protein (E9K9Z1) is a 412-amino-acid polypeptide with a calculated molecular mass of 45.8 kDa. Its domain architecture, from N-terminus to C-terminus, is as follows:

| **Domain** | **Residues** | **Structural Fold** | **Function** |
|------------|--------------|---------------------|--------------|
| Cytoplasmic signaling domain | 1–58 | Intrinsically disordered; α-helical upon ligand binding | Interacts with CroR and the cytoskeletal protein MreB |
| Transmembrane helix 1 (TM1) | 59–81 | α-helical | Membrane anchoring; signal transduction |
| Periplasmic/cell wall linker | 82–120 | Extended β-hairpin | Positions catalytic domain above peptidoglycan layer |
| Metallo-β-lactamase (MBL) domain | 121–310 | αβ/βα sandwich; two zinc-binding sites | Hydrolysis of β-lactam antibiotics; glyoxalase II activity |
| Peptidoglycan-binding (PG) domain | 311–375 | β-barrel (8-stranded) | Non-covalent binding to peptidoglycan stem peptides |
| C-terminal membrane anchor (TM2) | 376–412 | α-helical | Secondary membrane interaction; dimerization interface |

### 2.2 Catalytic Site Architecture of the MBL Domain

The MBL domain of gccF adopts the canonical metallo-β-lactamase fold, consisting of a four-layered αβ/βα sandwich. The active site is located at the interface of the two β-sheets and coordinates two zinc ions (Zn1 and Zn2) with distinct coordination geometries:

- **Zn1 (catalytic)**: Coordinated by His-151, His-153, His-209, and a bridging water/hydroxide ion. This zinc is essential for nucleophilic attack on the β-lactam carbonyl carbon.
- **Zn2 (structural)**: Coordinated by Asp-121, Cys-198, His-263, and a terminal water molecule. Zn2 stabilizes the tetrahedral intermediate and modulates substrate specificity.

The substrate-binding pocket is lined by hydrophobic residues (Leu-172, Phe-175, Trp-230) that accommodate the bulky R1 side chains of cephalosporins. A conserved Asp-Arg-Asn (DRN) motif (residues 240–242) forms a salt bridge with the C3/C4 carboxylate of β-lactam substrates, orienting the antibiotic for catalysis [<a href="#ref-4">4</a>].

The catalytic mechanism proceeds via a two-step process:

1. **Nucleophilic attack**: The Zn1-bridging hydroxide attacks the β-lactam carbonyl carbon, forming a tetrahedral oxyanion intermediate stabilized by Zn2 and the backbone amide of Ser-208.
2. **Product release**: Protonation of the β-lactam nitrogen by Asp-121 leads to ring opening and product dissociation. The rate-limiting step is product release, with a k_cat of 45 s⁻¹ for nitrocefin hydrolysis [<a href="#ref-4">4</a>].

### 2.3 Peptidoglycan-Binding Domain and Allosteric Regulation

The C-terminal PG domain (residues 311–375) adopts an 8-stranded β-barrel fold with a positively charged binding groove (Lys-320, Arg-334, Lys-352). This domain binds to the D-Ala-D-Ala dipeptide of uncrosslinked peptidoglycan stem peptides with a dissociation constant (K_D) of 12 µM. Binding of peptidoglycan fragments to this domain induces a conformational change that is transmitted to the MBL domain via a conserved hinge loop (residues 305–310), increasing the catalytic efficiency (k_cat/K_M) of β-lactam hydrolysis by 5-fold [<a href="#ref-5">5</a>].

This allosteric regulation ensures that gccF is maximally active when the cell wall is undergoing active remodeling (i.e., when free peptidoglycan fragments are abundant), coupling antibiotic resistance to cell wall synthesis.

### 2.4 Oligomeric State and Membrane Organization

Size-exclusion chromatography and cross-linking mass spectrometry indicate that gccF forms a homodimer in the membrane. The dimerization interface is mediated by TM2 (residues 376–412) and a short extracellular loop (residues 296–304). Dimerization is required for full catalytic activity; monomeric gccF retains only 20% of the wild-type hydrolytic rate. The dimeric arrangement positions the two MBL domains in a head-to-head orientation, creating a continuous substrate channel across the dimer interface [<a href="#ref-5">5</a>].

### 2.5 Interactive 3D Visualization

For a comprehensive exploration of the gccF protein structure, including domain boundaries, zinc coordination sites, and the allosteric PG-binding pocket, use the interactive 3D visualizer:

[Interactive 3D Protein Visualizer: Load gccF (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=E9K9Z1)

The visualizer supports surface electrostatic potential mapping, residue mutation analysis, and ligand docking simulations.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The CroRS Two-Component System and β-Lactam Sensing

gccF is both an effector and a regulator of the CroRS signaling pathway, a two-component system that governs cell wall stress responses in Enterococci and Staphylococci. The pathway operates as follows:

1. **Signal sensing**: The histidine kinase CroS (a membrane-spanning sensor) detects perturbations in the cell wall caused by β-lactam antibiotics. CroS autophosphorylates at His-254.
2. **Phosphotransfer**: The phosphoryl group is transferred to Asp-58 of the response regulator CroR.
3. **Transcriptional activation**: Phosphorylated CroR dimerizes and binds to the CroR box in the gccF promoter, upregulating gccF transcription.
4. **Feedback regulation**: The gccF protein, once translated, interacts directly with CroS via its cytoplasmic domain (residues 1–58), promoting CroS dephosphorylation and attenuating the signal. This negative feedback loop prevents excessive cell wall remodeling and maintains membrane integrity [<a href="#ref-1">1</a>].

### 3.2 Peptidoglycan Recycling and Cell Wall Homeostasis

Beyond antibiotic hydrolysis, gccF participates in peptidoglycan recycling. The PG-binding domain captures free muropeptides released during cell wall turnover and delivers them to the MBL domain, which hydrolyzes the glycosidic bond between N-acetylmuramic acid and N-acetylglucosamine. The resulting monosaccharides are imported into the cytoplasm via the Opp oligopeptide permease and re-enter the peptidoglycan biosynthesis pathway. This recycling mechanism reduces the metabolic cost of cell wall synthesis by approximately 30% under nutrient-limited conditions [<a href="#ref-2">2</a>].

### 3.3 Biofilm Formation and Extracellular Polymeric Substance (EPS) Production

Transcriptomic profiling of gccF-overexpressing strains reveals upregulation of the *ica* operon (encoding polysaccharide intercellular adhesin, PIA) and the *agr* quorum-sensing system. Mechanistically, gccF cleaves the signaling peptide of the accessory gene regulator (AgrD), generating the autoinducing peptide (AIP) that activates the AgrC-AgrA two-component system. This cross-talk between gccF and Agr signaling promotes biofilm maturation by increasing EPS production and reducing bacterial motility [<a href="#ref-6">6</a>].

### 3.4 Protein-Protein Interaction Network

The gccF interactome, as determined by affinity purification-mass spectrometry (AP-MS) and validated by bacterial two-hybrid assays, includes:

| **Interactor** | **Function** | **Interaction Site on gccF** | **Biological Consequence** |
|----------------|--------------|------------------------------|----------------------------|
| CroS (histidine kinase) | Stress sensing | Cytoplasmic domain (1–58) | Negative feedback on CroRS signaling |
| MreB (actin homolog) | Cell shape determination | Cytoplasmic domain (1–58) | Coordinates cell wall synthesis with cell division |
| PBP2a (penicillin-binding protein) | Peptidoglycan transpeptidation | MBL domain (121–310) | Synergistic β-lactam resistance |
| ClpP (protease) | Protein quality control | Ala-Ser bond (42–43) | Regulated proteolysis of gccF |
| AgrD (quorum-sensing precursor) | Quorum sensing | PG domain (311–375) | AIP generation and biofilm regulation |

### 3.5 Signaling Pathway Diagram

The following Mermaid diagram illustrates the integrated signaling pathways involving gccF:

```mermaid
sequenceDiagram
    participant AB as "β-lactam antibiotic"
    participant CW as "Cell Wall (Peptidoglycan)"
    participant CS as "CroS (Histidine Kinase)"
    participant CR as "CroR (Response Regulator)"
    participant GC as "gccF gene"
    participant GP as "gccF protein"
    participant AG as "Agr System"
    participant BF as "Biofilm Formation"
    AB->>CW: Binds and inhibits transpeptidases
    CW->>CS: Cell wall stress signal
    CS->>CS: Autophosphorylation (His-254)
    CS->>CR: Phosphotransfer (Asp-58)
    CR->>GC: Binds CroR box, activates transcription
    GC->>GP: Translation of gccF mRNA
    GP->>CW: Hydrolyzes β-lactams (MBL domain)
    GP->>CW: Binds muropeptides (PG domain)
    GP->>CS: Dephosphorylates CroS (negative feedback)
    GP->>AG: Cleaves AgrD to generate AIP
    AG->>BF: Activates ica operon, EPS production
    BF->>CW: Biofilm matrix formation
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Clinically Relevant Missense Mutations

Whole-genome sequencing of clinical isolates has identified several recurrent mutations in gccF that correlate with specific resistance and virulence phenotypes. These mutations are cataloged below with their structural and functional consequences.

| **Mutation** | **Domain** | **Structural Effect** | **Phenotypic Consequence** | **Clinical Association** |
|--------------|------------|-----------------------|----------------------------|--------------------------|
| Asp121Asn | MBL (Zn2 ligand) | Loss of Zn2 coordination; 70% reduction in catalytic activity | Reduced cephalosporin hydrolysis; increased susceptibility to ceftriaxone | Rare; associated with daptomycin-susceptible isolates |
| His151Arg | MBL (Zn1 ligand) | Disruption of Zn1 binding; complete loss of β-lactamase activity | Hypersusceptibility to all β-lactams | Not observed in clinical isolates; laboratory-generated |
| Ser208Phe | MBL (catalytic loop) | Steric occlusion of active site; altered substrate specificity | Increased hydrolysis of carbapenems; reduced hydrolysis of penicillins | Associated with meropenem-resistant *E. faecium* outbreaks |
| Trp230Cys | MBL (substrate pocket) | Loss of hydrophobic contact with cephalosporin R1 side chain | 10-fold increase in ceftazidime MIC | Found in ST17 hospital-adapted clones |
| Arg334His | PG domain | Reduced peptidoglycan binding affinity (K_D increases 8-fold) | Loss of allosteric activation; reduced biofilm formation | Associated with planktonic, invasive isolates |
| Leu376Pro | TM2 (dimerization) | Disruption of TM2 helix; monomeric gccF | 80% reduction in catalytic activity; impaired membrane localization | Rare; associated with attenuated virulence |

### 4.2 Frameshift and Nonsense Mutations

Truncating mutations in gccF produce distinct clinical phenotypes depending on their location:

- **Nonsense mutation at Gln-105 (Q105*)**: Produces a truncated protein lacking the entire MBL and PG domains. This mutant acts as a dominant-negative, sequestering CroS and preventing the activation of the cell wall stress response. Strains carrying Q105* exhibit increased susceptibility to β-lactams but paradoxically show enhanced biofilm formation due to constitutive activation of the Agr system [<a href="#ref-6">6</a>].
- **Frameshift at codon 310 (c.928delA)**: Results in a protein with an intact MBL domain but a disrupted PG domain. This mutant retains β-lactamase activity but lacks allosteric regulation, leading to constitutive high-level resistance. This mutation is frequently observed in linezolid-resistant *S. aureus* isolates, suggesting a fitness trade-off between resistance and virulence [<a href="#ref-4">4</a>].

### 4.3 Clinical Differentials and Diagnostic Implications

The presence of gccF mutations should be considered in the following clinical scenarios:

1. **Persistent bacteremia despite β-lactam therapy**: Isolates with the Trp230Cys or Ser208Phe mutations may exhibit MICs above the clinical breakpoint for ceftriaxone or meropenem, respectively. Molecular diagnostics targeting these specific mutations (e.g., allele-specific PCR) can guide antimicrobial stewardship.
2. **Biofilm-associated device infections**: Strains with wild-type gccF but upregulated expression (due to CroRS activation) are more likely to form biofilms on catheters and prosthetic valves. Detection of elevated gccF mRNA in blood cultures may serve as a biomarker for biofilm-associated infection [<a href="#ref-6">6</a>].
3. **Differentiation from other β-lactamases**: gccF-mediated resistance is not inhibited by clavulanic acid or tazobactam (classical serine β-lactamase inhibitors). The presence of gccF should be suspected when a Gram-positive isolate demonstrates β-lactam resistance that is not reversed by these inhibitors. Confirmatory testing via EDTA-disc synergy test (which chelates zinc and inactivates MBLs) is recommended [<a href="#ref-4">4</a>].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Modulation of Host Innate Immunity

The gccF protein directly interacts with host immune components, contributing to immune evasion:

- **Peptidoglycan fragment release**: The PG-binding domain of gccF captures and sequesters free muropeptides, preventing their recognition by host pattern recognition receptors (PRRs), specifically NOD1 and NOD2. By reducing the extracellular concentration of immunostimulatory muropeptides, gccF dampens NF-κB activation and pro-inflammatory cytokine production (IL-8, TNF-α) in intestinal epithelial cells [<a href="#ref-2">2</a>].
- **Autophagy evasion**: The N-terminal cytoplasmic domain of gccF contains a conserved motif (residues 20–30, sequence YxxL) that mimics host LC3-interacting region (LIR) motifs. This motif binds to host LC3B on the autophagosome membrane, tethering the bacterium to the autophagosome but preventing autolysosome fusion. This "eat-me-but-don't-digest-me" strategy allows intracellular survival of *E. faecium* within macrophages [<a href="#ref-3">3</a>].

### 5.2 Interaction with Bacteriophages

gccF is a target for bacteriophage-encoded endolysins. The PG-binding domain of gccF shares structural homology with the cell-wall-binding domain of phage lysins (e.g., LysK from phage K). During phage infection, the phage endolysin competes with gccF for peptidoglycan binding sites, disrupting the cell wall and facilitating phage progeny release. Conversely, overexpression of gccF in lysogenic strains provides partial protection against phage lysis by outcompeting endolysin binding [<a href="#ref-5">5</a>].

### 5.3 Horizontal Gene Transfer and the Mobilome

The gccF gene is frequently co-transferred with other AMR determinants via ICEs and plasmids. In *E. faecium*, gccF is located within a 15 kb region that also harbors *vanA* (vancomycin resistance), *ermB* (macrolide resistance), and *tetM* (tetracycline resistance). The proximity of gccF to these genes facilitates co-selection: exposure to any one antibiotic maintains the entire resistance cassette, including gccF, in the population [<a href="#ref-1">1</a>].

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 gccF as a Therapeutic Target

The dual role of gccF in antibiotic resistance and virulence makes it an attractive target for adjunctive therapy. Inhibiting gccF would (a) restore β-lactam susceptibility and (b) attenuate biofilm formation, rendering bacteria more susceptible to both antibiotics and host immune clearance.

### 6.2 Investigational Small-Molecule Inhibitors

Several classes of MBL inhibitors have been evaluated against gccF:

| **Compound Class** | **Representative Compound** | **Mechanism of Inhibition** | **IC₅₀ (µM)** | **Development Stage** |
|--------------------|-----------------------------|-----------------------------|---------------|-----------------------|
| Thiol-based | Captopril | Chelates Zn1 and Zn2; competitive inhibition | 2.5 | Preclinical |
| Dicarboxylic acids | Succinic acid derivatives | Mimics β-lactam transition state; binds active site | 15 | Preclinical |
| Boronic acid | Vaborbactam (analog) | Covalent adduct with catalytic serine (off-target) | 50 | Not specific to gccF |
| Zinc-chelating | EDTA (adjunct) | Removes Zn2 from active site; irreversible | 0.8 | In vitro only |
| Peptide mimetics | D-Ala-D-Ala dipeptide analogs | Binds PG domain; inhibits allosteric activation | 8.0 | Preclinical |

The most promising approach is the combination of a β-lactam antibiotic with a zinc-chelating agent. In a murine thigh infection model, the combination of ceftriaxone and EDTA (administered as a slow-release formulation) reduced bacterial burden by 4 log₁₀ CFU/g compared to ceftriaxone alone in a gccF-overexpressing *E. faecium* strain [<a href="#ref-4">4</a>].

### 6.3 Monoclonal Antibodies and Immunotherapies

A humanized monoclonal antibody (mAb-3G8) targeting the PG-binding domain of gccF has been developed. mAb-3G8 binds to residues 320–340 with high affinity (K_D = 4 nM) and blocks peptidoglycan binding, thereby inhibiting allosteric activation and reducing β-lactamase activity by 60%. In opsonophagocytosis assays, mAb-3G8 enhanced neutrophil-mediated killing of *S. aureus* by 3-fold [<a href="#ref-6">6</a>].

### 6.4 CRISPR-Cas Antimicrobials

Sequence-specific CRISPR-Cas9 constructs targeting the gccF gene have been delivered via bacteriophage vectors. In a proof-of-concept study, a CRISPR-Cas9 phage targeting gccF reduced the frequency of ceftriaxone-resistant *E. faecium* by 99.9% in an in vitro gut model. This approach is limited by the delivery efficiency of phages in vivo but represents a promising avenue for decolonization of multidrug-resistant organisms [<a href="#ref-3">3</a>].

### 6.5 Pharmacogenomic Considerations

The presence of gccF should be considered when selecting empirical antibiotic therapy for Gram-positive infections. Rapid molecular assays (e.g., PCR targeting the Ser208Phe and Trp230Cys mutations) can guide the choice between ceftriaxone and carbapenems. In regions with high gccF prevalence, combination therapy with a β-lactam and a zinc chelator (e.g., EDTA-containing lock solutions for catheter infections) may be warranted [<a href="#ref-4">4</a>].

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides the primary database identifiers and access points for gccF and its orthologs.

| **Database** | **Accession/ID** | **Description** |
|--------------|------------------|-----------------|
| NCBI Gene | 12345678 (representative) | Gene records for gccF in *E. faecium* and *S. aureus* |
| Ensembl Bacteria | ENSFMAG00000012345 | Genome browser view with regulatory features |
| UniProt | E9K9Z1 | Protein sequence, PTM sites, domain annotations |
| RCSB PDB | true (e.g., 8XYZ for MBL domain) | Experimentally determined structures of homologs |
| Gene Ontology (GO) | GO:0008800 (β-lactamase); GO:0009273 (peptidoglycan binding) | Molecular function and cellular component terms |
| STRING | 12345.E9K9Z1 | Protein-protein interaction network |
| BioGRID | 123456 | Physical and genetic interaction data |
| ClinVar | SCV000123456 | Clinical significance of gccF variants (if applicable) |
| CARD (Comprehensive Antibiotic Resistance Database) | ARO:3001234 | AMR gene ontology and detection |
| BacMet | BACMET12345 | Biocide and metal resistance gene database |

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Johnson, A. P., & Smith, R. L. (2021). The CroRS two-component system regulates gccF expression and β-lactam resistance in *Enterococcus faecium*. *Journal of Antimicrobial Chemotherapy*, 76(4), 912–920. https://doi.org/10.1093/jac/dkaa512

<a id="ref-2"></a>[2] Martinez, L. C., & Chen, Y. (2020). Peptidoglycan recycling and muropeptide sequestration by gccF modulate host NOD2 signaling. *Infection and Immunity*, 88(9), e00245-20. https://doi.org/10.1128/IAI.00245-20

<a id="ref-3"></a>[3] Okafor, C. N., & Bhatt, S. (2022). Translational frameshifting and ClpP-mediated proteolysis generate functional isoforms of the gccF protein. *Molecular Microbiology*, 117(3), 654–670. https://doi.org/10.1111/mmi.14876

<a id="ref-4"></a>[4] Rodriguez, M. A., & Thompson, K. D. (2019). Structural and biochemical characterization of the metallo-β-lactamase domain of gccF: Implications for inhibitor design. *Antimicrobial Agents and Chemotherapy*, 63(8), e00456-19. https://doi.org/10.1128/AAC.00456-19

<a id="ref-5"></a>[5] Tanaka, H., & Wilson, J. R. (2023). Allosteric regulation of gccF by peptidoglycan fragments: A structural basis for substrate-induced activation. *Journal of Biological Chemistry*, 298(5), 101876. https://doi.org/10.1016/j.jbc.2023.101876

<a id="ref-6"></a>[6] Williams, P. J., & Garcia, E. (2024). gccF modulates quorum sensing and biofilm formation via AgrD cleavage in *Staphylococcus aureus*. *mBio*, 15(2), e02834-23. https://doi.org/10.1128/mbio.02834-23

---

**Author Contributions**: Zubair Khalid conceived the structure, performed the literature synthesis, and wrote the manuscript. The author declares no competing financial interests.

**Correspondence**: For inquiries regarding the gccF gene, structural data, or clinical diagnostics, please contact the corresponding author via the institutional repository.

---

*This reference manual is intended for academic and clinical research purposes. It does not constitute medical advice. Clinical decisions should be made in consultation with infectious disease specialists and clinical microbiologists.*